Literature DB >> 18570304

Yield of additional metabolic studies in neurodevelopmental disorders.

Hannelie M Engbers1, Ruud Berger, Peter van Hasselt, Tom de Koning, Monique G M de Sain-van der Velden, Hester Y Kroes, Gepke Visser.   

Abstract

The timing and yield of metabolic studies for patients with neurodevelopmental disorders is a matter of continuing debate. We determined the yield of additional or repeated metabolic studies in patients with neurodevelopmental disorders. Patients referred to a tertiary diagnostic center for patients with unexplained neurodevelopmental disorders were included. Initial metabolic studies had been performed in most patients (87%) before referral. Additional/repeated metabolic studies were individually tailored. Twelve metabolic diseases of 433 patients studied (2.8%) were diagnosed, despite normal initial metabolic studies before referral. Specific metabolic investigations lead to a greater diagnostic yield in patients with neurodevelopmental disorders.

Entities:  

Mesh:

Year:  2008        PMID: 18570304     DOI: 10.1002/ana.21435

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

Review 1.  Medical comorbidities in autism: challenges to diagnosis and treatment.

Authors:  Margaret L Bauman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

2.  Early identification of treatable inborn errors of metabolism in children with intellectual disability: The Treatable Intellectual Disability Endeavor protocol in British Columbia.

Authors:  Clara Dm van Karnebeek; Sylvia Stockler-Ipsiroglu
Journal:  Paediatr Child Health       Date:  2014-11       Impact factor: 2.253

3.  Genetic Approach to Diagnosis of Intellectual Disability.

Authors:  Ratna Dua Puri; Moni Tuteja; I C Verma
Journal:  Indian J Pediatr       Date:  2016-09-13       Impact factor: 1.967

4.  Diagnostic yield from routine metabolic screening tests in evaluation of global developmental delay and intellectual disability.

Authors:  Hilary Vallance; Graham Sinclair; Bojana Rakic; Sylvia Stockler-Ipsiroglu
Journal:  Paediatr Child Health       Date:  2020-12-19       Impact factor: 2.253

Review 5.  Next Generation Sequencing and Bioinformatics Analysis of Family Genetic Inheritance.

Authors:  Aquillah M Kanzi; James Emmanuel San; Benjamin Chimukangara; Eduan Wilkinson; Maryam Fish; Veron Ramsuran; Tulio de Oliveira
Journal:  Front Genet       Date:  2020-10-23       Impact factor: 4.599

Review 6.  Metabolic evaluation of children with global developmental delay.

Authors:  So-Hee Eun; Si Houn Hahn
Journal:  Korean J Pediatr       Date:  2015-04-22

7.  Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications.

Authors:  Gé-Ann Kuiper; Olga L M Meijer; Eveline J Langereis; Frits A Wijburg
Journal:  Orphanet J Rare Dis       Date:  2018-01-08       Impact factor: 4.123

8.  Diagnostic contribution of metabolic workup for neonatal inherited metabolic disorders in the absence of expanded newborn screening.

Authors:  Alexandra Bower; Apolline Imbard; Jean-François Benoist; Samia Pichard; Odile Rigal; Olivier Baud; Manuel Schiff
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

9.  Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.

Authors:  Glen R Monroe; Gerardus W Frederix; Sanne M C Savelberg; Tamar I de Vries; Karen J Duran; Jasper J van der Smagt; Paulien A Terhal; Peter M van Hasselt; Hester Y Kroes; Nanda M Verhoeven-Duif; Isaäc J Nijman; Ellen C Carbo; Koen L van Gassen; Nine V Knoers; Anke M Hövels; Mieke M van Haelst; Gepke Visser; Gijs van Haaften
Journal:  Genet Med       Date:  2016-02-04       Impact factor: 8.822

Review 10.  Current evidence-based recommendations on investigating children with global developmental delay.

Authors:  Renuka Mithyantha; Rachel Kneen; Emma McCann; Melissa Gladstone
Journal:  Arch Dis Child       Date:  2017-11       Impact factor: 3.791

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.